Date:12/16/2010

ral infection that can become serious enough to keep teens home from school, sports and other activities.  It can sometimes result in a visit to the hospital or lead to serious complications like pneumonia or even death.  Vaccination is the best protection against the spread of the influenza virus. The CDC recommends that everyone 6 months of age and older get vaccinated against influenza each year.  This year, the seasonal influenza vaccine includes the 2009 pandemic H1N1 strain, so only the seasonal influenza vaccine is needed. Vaccination begins as soon as vaccine becomes available, usually in August, and continues into spring or as long as the influenza virus is in circulation.  In most seasons, influenza virus activity peaks in February or March, so vaccination throughout the entire influenza season is beneficial and recommended.

Meningococcal Disease / Meningococcal MeningitisAlthough rare, meningococcal disease, including meningitis, is a serious, life-threatening infection that moves quickly and can lead to death within 24 to 48 hours of first symptoms.  Early symptoms may be similar to influenza, making it difficult for health-care providers to diagnose.  Currently, the CDC recommends that all preteens and teens 11 through 18 years of age be vaccinated against meningococcal disease at the earliest possible health-care visit – ideally, during the routine 11- or 12-year-old check-up.

Pertussis, Commonly Called "Whooping Cough"Pertussis is one of the most common respiratory diseases in American teens and adults. It causes a prolonged cough that can last weeks or months and can result in pneumonia or hospitalization.   Teens and adults can spread pertussis to younger children, who can develop a life-threatening pertussis infection.  The CDC recommends a single booster dose of Tdap vaccine for people 11 through 64 years of age; immunity to the pertussis vaccine decreases over time,
'/>"/>

SOURCE Society for Adolescent Health and Medicine Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. WorldHeart Announces First U.S. Implant of Levacor(TM) VAD Implant at INTEGRIS in Oklahoma City
2. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
3. Quark Pharmaceuticals Appoints New Chief Medical Officer
4. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
5. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
6. AIDS Vaccine Advocacy Coalition Voices Disappointment in Trial Result
7. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
8. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
9. West Pharmaceutical Services, Inc. Appoints New Director
10. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
11. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance